Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: GlobeNewswire
Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative blockbuster products for inflammatory back pain and heart failure Announces close of enrollment for Phase 3 trial for CLBP at the end of this month Highlights label extension strategy for Ryoncil® in adult and pediatric rare diseases: - Adult SR-aGvHD trial cleared by central institutional review board (IRB), first sites to be activated this quarter - FDA cleared IND to directly proceed to registrational trial for approval of Ryoncil® in children with Duchenne muscular dystrophy (DMD) Announces acquisition of a patented CAR technology platform developed at Mayo Clinic for precision-enhanced augmentation of the Company’s proprietary MSC products Company will webcast its R&D Day event today at 8:00 a.m. EST NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell ProductsGlobeNewswire
- ASX April 2026 Stocks Estimated To Be Trading Below Fair Value [Yahoo! Finance]Yahoo! Finance
- Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTIONGlobeNewswire
- Mesoblast R&D Day: Ryonsel Gains Traction, Back Pain Phase III Nears Finish, New Shots on Goal [Yahoo! Finance]Yahoo! Finance
- Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy [Yahoo! Finance]Yahoo! Finance
MESO
Sec Filings
- 4/13/26 - Form 4
- 4/10/26 - Form 4
- 4/1/26 - Form 3
- MESO's page on the SEC website